Literature DB >> 6226710

Neurinoma of the oculomotor nerve. Case report.

T Kansu, O E Ozcan, E Ozdirim, B Onol, O Gürcay.   

Abstract

A 15-year-old boy with a recurrent third nerve palsy who was found to have a neurinoma of the third nerve is described. Unusual features of his presentation and review of the literature relative to this rare tumor are discussed. Tumors derived from Schwann cells, which wrap around the axons of peripheral nerves, are called neurinomas, neurofibromas, plexiform neurofibromas, neurilemomas, and schwannomas. Neurinomas are usually localized in the peripheral nerves. The most frequent site of occurrence of an intracranial schwannoma is the acoustic nerve; however, the tumor may occur along the second, fifth, seventh, 11th, and 12th cranial nerves. Neurinomas of the oculomotor nerves are extremely rare. In the literature, there are only four reported cases clinically manifested and pathologically verified as neurinomas of the third nerve.

Entities:  

Mesh:

Year:  1982        PMID: 6226710

Source DB:  PubMed          Journal:  J Clin Neuroophthalmol        ISSN: 0272-846X


  4 in total

1.  Schwannoma of extraocular nerves: survey of literature and case report of an isolated third nerve schwannoma.

Authors:  W Niazi; J E Boggan
Journal:  Skull Base Surg       Date:  1994

2.  Relapsing-Remitting Sixth Nerve Palsy in Association with Ollier's Disease.

Authors:  Naz Raoof; Ruth Batty; Thomas A Carroll; Irene M Pepper; Ann Sandison; Rupert Eckersley; Simon J Hickman
Journal:  Neuroophthalmology       Date:  2015-02-03

Review 3.  Management of oculomotor nerve schwannomas in two different locations: surgical nuances and comprehensive review.

Authors:  Sunil V Furtado; Alangar S Hegde
Journal:  Neurosurg Rev       Date:  2011-07-26       Impact factor: 3.042

4.  Oculomotor nerve schwannoma associated with acute hydrocephalus: case report.

Authors:  Keiya Iijima; Masahiko Tosaka; Takuro Nagano; Hiroyuki Yaoita; Nozomi Matsumura; Yoichi Nakazato; Yuhei Yoshimoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-20       Impact factor: 1.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.